Amyris Announces Pricing of a $300 0 Million Public Offering (Secondary and Primary) of Common Stock prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Amyris Announces Proposed Public Offering (Secondary And Primary) Of Common Stock
News provided by
Share this article
Share this article
EMERYVILLE, Calif., April 7, 2021 /PRNewswire/ Amyris, Inc. (Nasdaq: AMRS) ( Amyris ), a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer brands and a top supplier of sustainable and natural ingredients, today announced the commencement of a proposed underwritten public offering of shares of its common stock.
Amyris is conducting a resale of stock on behalf of its current stockholders, DSM International B.V. and affiliates of Vivo Capital LLC (the selling stockholders). The selling stockholders intend to offer an aggregate of $150.0 million of shares of Amyris s common stock. Amyris will not receive any proceeds from the sale of the shares by the selling stockholders. Additionally, Amyris intends to offer $100.0 million of shares of its common stock to support its continued growth.
Seattle biotech firm Impel NeuroPharma files for $75M IPO
April 5, 2021 at 8:41 am News Brief
Impel CEO Adrian Adams. (Impel Photo)
Seattle-based biotech company Impel NeuroPharma is set to go public. The company, which develops central nervous system disorders such as migraines and Parkinson’s, submitted paperwork on Friday for a $75 million IPO.
Founded in 2008, Impel is a late-stage pre-revenue pharma company known for its Precision Olfactory Delivery (POD) platform, which sends drugs into the nasal cavity with the goal of penetrating the blood-brain barrier and targeting the organ more directly than is possible with pills or injected drugs. Its lead candidate, a drug that treats migraines called TRUDHESA, is going through the FDA’s New Drug Application process.
VISEN s TransCon Human Growth Hormone Phase-III Clinical Trial in China Completes Target Patient Recruitment Number as Scheduled biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.
New Science Ventures Portfolio Company Ventyx Biosciences Raises $114 Million
Ventyx Biosciences combines clinical stage programs of three companies co-founded and merged by New Science Ventures
News provided by
Share this article
Share this article
NEW YORK and LONDON, March 9, 2021 /PRNewswire/ New Science Ventures LLC ( NSV ), a leading venture capital firm focused on building companies that leverage breakthrough science to create extraordinary value, announces that its portfolio company Ventyx Biosciences raised $114 million from blue-chip investors to advance a diverse pipeline of immunology programs.
Ventyx Biosciences combines assets from three formerly independent, asset-centric companies – Oppilan Pharma (targeting S1P1R), Zomagen Biosciences (targeting the NLRP3 inflammasome) and the original Ventyx Biosciences (targeting TYK2) – which were founded and merged by Raju Mohan, CEO of Ventyx Biosciences, and New Science Ventures.